The export momentum of raw material medicines based on low-price competition has apparently slowed down in the past year. Customs statistics show that out of the 65 key chemical exporter products that are tracked, about 40% of the export volume of varieties has declined. According to industry insiders, the export of APIs based on low-price competition is difficult to sustain. Increased cost pressures and an increase in uncertainties in the external economic environment have also added a fog to the outlook for APIs exports.
Experts in the industry pointed out that the raw material medicine industry is currently facing more challenges than opportunities, and finding varieties suitable for international market development and having sustainable development advantages becomes an urgent issue for breakthroughs in API companies. Turning to high value-added small varieties, turning to new demand markets, and further enhancing environmental protection technologies will be one of the trends in the transformation of raw material pharmaceutical production enterprises. The market potential of fermented glutathione and fermented semi-synthetic orlistat is worth looking forward to.
The export pattern changed again in 2011, China's raw material medicine exports under the envelope of the debt crisis in Europe and the United States under a certain pressure. According to customs statistics, 75 chemical raw materials and preparations that were tracked in 2011 showed a decrease of 5% in the volume of raw material medicine exports compared with the same period of last year. Of the 65 key raw materials exported, the export volume of about 40% of the varieties declined.
From the perspective of export regions, exports to Asia increased steadily, and the average export prices also increased by about 6% from the previous year; exports to Europe continued to decline, which fell by 9.5% year-on-year, but the average price rose by 12.5%; the basic export prices to North America Compared with the previous year, the growth rate of South American export volume has gone out of the parabolic downwards, but the price has increased by 23% year-on-year; the export volume to Africa has increased the highest, reaching 9.6%, and the average price has also increased by 5.5%.
The United States, India, and Germany are still the top three countries in China that purchase raw material medicines. Among the top 20 major trading nations, there are five countries with volume and price drops, namely Germany, France, Belgium, Italy and India. The fastest growing trade volume has been for emerging countries such as Russia, Mexico, Vietnam, Thailand and Indonesia.
Wu Huifang, general manager of Beijing Dongfang Bit Technology pointed out that most of China's export of APIs is concentrated in Asian countries, followed by EU and North American countries. These regions have high demand for generic drugs, APIs, and synthetic pharmaceutical intermediates. However, the demand for APIs varies from country to country. For example, Vietnam is based on amino acids, vitamins, and antibiotics; Mexico is mainly based on food additives and feed antibiotics.
There are 25 common names for varieties with more than US$100 million worth of exports, an increase of three kinds compared to 2010, mainly concentrated on vitamins, food additives, and antibiotic raw materials. Among them, heparin sodium topped the list again with a total of US$900 million; citric acid rose from the fourth place last year to second; vitamin C and vitamin E ranked third and fourth respectively; penicillin industrial salt and azithromycin were exported The amount dropped below US$100 million.
Even so, the bulk of low-cost antibiotics continued to be the largest exporter of pharmaceuticals for US$3.269 billion in exports. The billion-dollar varieties are 6-APA, amoxicillin, chlortetracycline, erythromycin cyanate, and doxycycline. However, Wu Huifang said that these varieties basically reach a certain degree of market saturation, and there is little room for growth. New entrants will easily cause price wars.
Looking for new growth points It is worth noting that vitamin C, penicillin and other proprietary Chinese proprietary APIs have caused export prices to decline or transactions to shrink due to high domestic production capacity or excessive competition. At the same time, however, the prices of some monopolized and resource-based APIs, such as heparin sodium, continue to rise, and domestic API companies urgently need to shift to new market demands.
Wu Huifang pointed out that in the era of high prices of erythromycin cyanide and high prices, there is an opportunity for this generation of erythromycin which is high in erythromycin with high content, low impurity, and stable downstream product quality. Even more noteworthy, this is mainly because the process route of the second-generation macrolides in European and American companies is based on erythromycin base. In the case of persistently high prices of red, erythromycin base can be used as a drug and raw material for the first generation of erythromycin, and can also be used for the old varieties of second-generation macrolide intermediates. Should be given the attention of manufacturers.
At the same time, API manufacturers should also strive to tap new varieties that are suitable for international market expansion and have the advantage of sustainable development. Wu Huifang believes that in accordance with past experience, large-scale basic raw material medicines, products that are likely to cause pollution or high energy consumption should not be reintroduced, and some small-scale companies that involve relatively few competing enterprises may not be significant in the domestic market but are There are still varieties of space in the international market that are worth considering.
The market potential of fermented glutathione and fermented semisynthetic orlistat is promising. It is understood that domestic enterprises of reduced glutathione began to have production and exports. Due to the relatively weak domestic finished product market, the current product is mainly based on the international market. There are not many domestic production enterprises and the market size is not large. Larger.
In addition, Orlistat has a share of around 80% of the weight-loss pharmaceuticals market in China and globally. As the slimming drug expires with the Roche patent, there is no new product listed after the withdrawal from the market, orlistat. Opportunities for development in China and the global market should also be taken seriously by domestic manufacturers.
Wu Huifang also believes that some clinical applications have new varieties of alternatives, with small scale of production and sales, low production profits, and few production companies, such as promethazine, reserpine, lidoca, etc. It is not sunshine, but because the demand still exists and the supply gaps, it is a variety of opportunities. Other old breeds are also being developed for new uses, once again playing their value and role, and also bringing new market opportunities to manufacturers.
Experts in the industry pointed out that the raw material medicine industry is currently facing more challenges than opportunities, and finding varieties suitable for international market development and having sustainable development advantages becomes an urgent issue for breakthroughs in API companies. Turning to high value-added small varieties, turning to new demand markets, and further enhancing environmental protection technologies will be one of the trends in the transformation of raw material pharmaceutical production enterprises. The market potential of fermented glutathione and fermented semi-synthetic orlistat is worth looking forward to.
The export pattern changed again in 2011, China's raw material medicine exports under the envelope of the debt crisis in Europe and the United States under a certain pressure. According to customs statistics, 75 chemical raw materials and preparations that were tracked in 2011 showed a decrease of 5% in the volume of raw material medicine exports compared with the same period of last year. Of the 65 key raw materials exported, the export volume of about 40% of the varieties declined.
From the perspective of export regions, exports to Asia increased steadily, and the average export prices also increased by about 6% from the previous year; exports to Europe continued to decline, which fell by 9.5% year-on-year, but the average price rose by 12.5%; the basic export prices to North America Compared with the previous year, the growth rate of South American export volume has gone out of the parabolic downwards, but the price has increased by 23% year-on-year; the export volume to Africa has increased the highest, reaching 9.6%, and the average price has also increased by 5.5%.
The United States, India, and Germany are still the top three countries in China that purchase raw material medicines. Among the top 20 major trading nations, there are five countries with volume and price drops, namely Germany, France, Belgium, Italy and India. The fastest growing trade volume has been for emerging countries such as Russia, Mexico, Vietnam, Thailand and Indonesia.
Wu Huifang, general manager of Beijing Dongfang Bit Technology pointed out that most of China's export of APIs is concentrated in Asian countries, followed by EU and North American countries. These regions have high demand for generic drugs, APIs, and synthetic pharmaceutical intermediates. However, the demand for APIs varies from country to country. For example, Vietnam is based on amino acids, vitamins, and antibiotics; Mexico is mainly based on food additives and feed antibiotics.
There are 25 common names for varieties with more than US$100 million worth of exports, an increase of three kinds compared to 2010, mainly concentrated on vitamins, food additives, and antibiotic raw materials. Among them, heparin sodium topped the list again with a total of US$900 million; citric acid rose from the fourth place last year to second; vitamin C and vitamin E ranked third and fourth respectively; penicillin industrial salt and azithromycin were exported The amount dropped below US$100 million.
Even so, the bulk of low-cost antibiotics continued to be the largest exporter of pharmaceuticals for US$3.269 billion in exports. The billion-dollar varieties are 6-APA, amoxicillin, chlortetracycline, erythromycin cyanate, and doxycycline. However, Wu Huifang said that these varieties basically reach a certain degree of market saturation, and there is little room for growth. New entrants will easily cause price wars.
Looking for new growth points It is worth noting that vitamin C, penicillin and other proprietary Chinese proprietary APIs have caused export prices to decline or transactions to shrink due to high domestic production capacity or excessive competition. At the same time, however, the prices of some monopolized and resource-based APIs, such as heparin sodium, continue to rise, and domestic API companies urgently need to shift to new market demands.
Wu Huifang pointed out that in the era of high prices of erythromycin cyanide and high prices, there is an opportunity for this generation of erythromycin which is high in erythromycin with high content, low impurity, and stable downstream product quality. Even more noteworthy, this is mainly because the process route of the second-generation macrolides in European and American companies is based on erythromycin base. In the case of persistently high prices of red, erythromycin base can be used as a drug and raw material for the first generation of erythromycin, and can also be used for the old varieties of second-generation macrolide intermediates. Should be given the attention of manufacturers.
At the same time, API manufacturers should also strive to tap new varieties that are suitable for international market expansion and have the advantage of sustainable development. Wu Huifang believes that in accordance with past experience, large-scale basic raw material medicines, products that are likely to cause pollution or high energy consumption should not be reintroduced, and some small-scale companies that involve relatively few competing enterprises may not be significant in the domestic market but are There are still varieties of space in the international market that are worth considering.
The market potential of fermented glutathione and fermented semisynthetic orlistat is promising. It is understood that domestic enterprises of reduced glutathione began to have production and exports. Due to the relatively weak domestic finished product market, the current product is mainly based on the international market. There are not many domestic production enterprises and the market size is not large. Larger.
In addition, Orlistat has a share of around 80% of the weight-loss pharmaceuticals market in China and globally. As the slimming drug expires with the Roche patent, there is no new product listed after the withdrawal from the market, orlistat. Opportunities for development in China and the global market should also be taken seriously by domestic manufacturers.
Wu Huifang also believes that some clinical applications have new varieties of alternatives, with small scale of production and sales, low production profits, and few production companies, such as promethazine, reserpine, lidoca, etc. It is not sunshine, but because the demand still exists and the supply gaps, it is a variety of opportunities. Other old breeds are also being developed for new uses, once again playing their value and role, and also bringing new market opportunities to manufacturers.
Layer Lighting Solution,Lighting In Layers,Layer Lightin,Layer Lightin For Sale
Shenzhen AMB Technology Co., Ltd , https://www.birdscareled.com